Tieshi Zhu: NHANES Study Reveals Significant Mortality Risk With Clopidogrel Monotherapy After PCI
Platelets Journal shared an insightful post on LinkedIn:
“How does clopidogrel monotherapy compare to aspirin after PCI and DAPT?
Building on a recent Korean study that highlighted the efficacy of clopidogrel monotherapy following percutaneous coronary intervention (PCI) and standard dual antiplatelet therapy (DAPT), Zhu et al. (2025) conducted a retrospective analysis of the U.S. NHANES 1999–2018 cohort to compare all-cause mortality between clopidogrel and aspirin monotherapy under similar conditions.
Contrary to previous findings in Asian populations, the authors found that clopidogrel monotherapy was associated with increased risks of all-cause mortality, cardiac mortality, and stroke compared to aspirin monotherapy.”
Read the full article here:
Article: Clopidogrel monotherapy is associated with higher mortality risk compared to aspirin: a retrospective analysis of NHANES 1999–2018
Authors: Tieshi Zhu, Yong He, Yuzhang Bei, Hui Mai, and Le Zhao
Follow the newest developments in clotting science with Hemostasis Today.
-
Feb 25, 2026, 16:47Alan Nurden: Platelet Defects Explain Bleeding in EHDS Patients
-
Feb 25, 2026, 16:40Mohammed Almohammadi: Uniting Leaders in Laboratory Hematology at the 1st Saudi ISLH Joint Conference
-
Feb 25, 2026, 16:37Salihu Asimawu: Inflammation Is Not a Disease – Hats Off to the Heroes Inside Us
-
Feb 25, 2026, 16:34Michael Makris: Biomarin Has Decided to Withdraw Roctavian from the Market
-
Feb 25, 2026, 16:25Tagreed Alkaltham: The Blood Banker Personality
-
Feb 25, 2026, 16:17Sanjay Ahuja: Insightful Talk on 100 Years of VWD by Jorge Di Paola
-
Feb 25, 2026, 15:20Michael Shapiro։ Creating Real Pathways for Trainees in Preventive Cardiology
-
Feb 25, 2026, 15:15Ajay Kumar: Plasma Component Quality Control Standards
-
Feb 25, 2026, 15:09Wolfgang Miesbach: Efficacy, Safety and Thrombosis Signals in Haemophilia A/B with Inhibitors